The present disclosure generally relates to medical device products. More particularly, the present disclosure relates to medical device products including liquid drawing members.
Certain medical device products depend on liquid activation. One such medical device is a hydrophilic intermittent urinary catheter, in which the hydrophilic coating may be activated by direct contact of a liquid activation medium (e.g., liquid water) with the hydrophilic coating. Some of these medical device products achieve direct liquid contact by providing a package which contains the device and liquid, wherein the device is in direct contact with the liquid. In several of these products the liquid flows freely within the cavity of the package and has unobstructed access to the medical device. Because of the free flow of loose liquid within the package and unobstructed access to the device surface, it is easy to provide direct contact of the liquid medium with the device within the package.
One of the challenges of the medical device products described above is that the liquid can tend to spill from the package as the user handles the product and removes the device from the package for use. Accordingly, there is a need for products and packages that reduce the risk of liquid spillage from the package.
There are several aspects of the present subject matter which may be embodied separately or together in the devices and systems described and claimed below. These aspects may be employed alone or in combination with other aspects of the subject matter described herein, and the description of these aspects together is not intended to preclude the use of these aspects separately or the claiming of such aspects separately or in different combinations as set forth in the claims appended hereto.
In one aspect, a medical device product includes a package defining an interior cavity, an activating liquid located within the interior cavity of the package, and a medical device located within the interior cavity of the package. At least one portion of the medical device is activated by absorbing an amount of the activating liquid. Additionally, a liquid-drawing member is located within the interior cavity of the package. The liquid-drawing member absorbs any excess activating liquid within the cavity that was not absorbed by the at least one portion of the medical device.
In another aspect, a urinary catheter product includes a package defining an interior cavity, an activating liquid located within the interior cavity of the package, and a urinary catheter located within the interior cavity of the package. At least one portion of the catheter comprises a lubricious hydrophilic material that is activated by absorbing an amount of the activating liquid. Furthermore, a liquid-drawing member is located within the interior cavity of the package. The liquid-drawing member absorbs any excess activating liquid within the cavity that was not absorbed by the at least one portion of the catheter.
The embodiments disclosed herein are for the purpose of providing a description of the present subject matter, and it is understood that the subject matter may be embodied in various other forms and combinations not shown in detail. Therefore, specific embodiments and features disclosed herein are not to be interpreted as limiting the subject matter as defined in the accompanying claims.
At least one portion 18a of the medical device is activated by contact with the liquid 16. For example, the portion 18a may be activated by absorbing an amount of the activating liquid 16. When the medical device is a hydrophilic catheter, the activating liquid may hydrate/activate the hydrophilic coating of the catheter, making it more lubricious and easier to insert into a user's body.
The medical device product also includes a liquid-drawing member 20 that is located within the interior cavity 14 of the package 12. The liquid-drawing member 20 absorbs any excess activating liquid 16 within the cavity 14. Excess liquid is activating liquid 16 that was not absorbed by the at least one portion 18a of the medical device 18. The amount, or type, of the liquid-drawing member 20 within the package is tuned or enough to allow the at least one portion 18a of the medical device 18 to be activated by the activating liquid 16, while the liquid-drawing member 20 absorbs any excess liquid.
In one embodiment, the liquid-drawing member 20 may comprise a desiccant. The desiccant absorbs excess activating liquid 16 within the cavity 14 so that when the package 12 is opened, there is a reduced risk of the liquid 16 spilling out of the package 12. The liquid-drawing member 20 may include a hygroscopic agent. The hygroscopic agent may be a solid, liquid or gel. The hygroscopic agent may include at least one of a glycerol or a glycerol gel. The desiccant and the hygroscopic agent both promote drawing and absorption of excess activating liquid 16.
In the embodiment shown in
Other variations and combinations may also be employed without departing from the scope of the present disclosure.
It will be understood that the embodiments described above are illustrative of some of the applications of the principles of the present subject matter. Numerous modifications may be made by those skilled in the art without departing from the spirit and scope of the claimed subject matter, including those combinations of features that are individually disclosed or claimed herein. For these reasons, the scope hereof is not limited to the above description but is as set forth in the following claims, and it is understood that claims may be directed to the features hereof, including as combinations of features that are individually disclosed or claimed herein.
The present application is the U.S. National Stage Application of PCT Application No. PCT/US2021/029992, filed Apr. 29, 2021, which claims the benefit of and priority to U.S. Provisional Application No. 63/018,730, filed May 1, 2020, all of which is are hereby incorporated herein by reference.
Filing Document | Filing Date | Country | Kind |
---|---|---|---|
PCT/US2021/029992 | 4/29/2021 | WO |
Publishing Document | Publishing Date | Country | Kind |
---|---|---|---|
WO2021/222642 | 11/4/2021 | WO | A |
Number | Name | Date | Kind |
---|---|---|---|
5616119 | Davis | Apr 1997 | A |
6065597 | Pettersson et al. | May 2000 | A |
7380658 | Murray et al. | Jun 2008 | B2 |
9038822 | Barnell | May 2015 | B2 |
9095324 | Peck et al. | Aug 2015 | B2 |
20080319423 | Tanghoj | Dec 2008 | A1 |
20100087801 | Torstensen | Apr 2010 | A1 |
20140360896 | Torstensen | Dec 2014 | A1 |
20150265801 | Rostami | Sep 2015 | A1 |
20150306342 | Rostami et al. | Oct 2015 | A1 |
20160346072 | Kawashima | Dec 2016 | A1 |
20170015066 | Herrmann et al. | Jan 2017 | A1 |
20170152066 | Herrmann et al. | Jan 2017 | A1 |
20180021481 | Mn et al. | Jan 2018 | A1 |
20190224384 | Lundahl et al. | Jul 2019 | A1 |
20230166075 | Farrell | Jun 2023 | A1 |
Number | Date | Country |
---|---|---|
1312385 | May 2003 | EP |
2060296 | May 2009 | EP |
2000281144 | Oct 2000 | JP |
2001130634 | May 2001 | JP |
2014093056 | Jun 2014 | WO |
2015065725 | May 2015 | WO |
Entry |
---|
International Search Report and Written Opinion for PCT/US2021/029992 Dated Sep. 16, 2021. |
Number | Date | Country | |
---|---|---|---|
20230166075 A1 | Jun 2023 | US |
Number | Date | Country | |
---|---|---|---|
63018730 | May 2020 | US |